Should Androgen Receptor Targeting Be Given Earlier for Prostate Cancer?

Charles J. Ryan, MD, University of California, discusses the advantages of giving androgen receptor targeting earlier to advanced disease patients, and a review of the STAMPEDE results.

To view slides from Dr. Ryan’s androgen receptor presentation at the 18th Annual Future Directions in Urology Symposium, click here.

To view slides from Dr. Ryan’s STAMPEDE results presentation at the 18th Annual Future Directions in Urology Symposium, click here.

“Keywords: prostate cancer, androgen receptor, STAMPEDE

ABOUT THE AUTHOR

About The Author

Charles J. Ryan, MD, is the President and Chief Executive Officer for The Prostate Cancer Foundation in Santa Monica, California. Dr. Ryan is an internationally recognized genitourinary (GU) oncologist with expertise in the biology and treatment of advanced prostate cancer. Dr. Ryan graduated magna cum laude with a BA in Philosophy from Marquette University. He then went on to attend the University of Wisconsin Medical School. He trained at the University of Wisconsin Hospital and Clinics, serving as Chief Resident, and at Memorial Sloan-Kettering Cancer Center in New York. He has served as Co-Chair of the National Cancer Institute’s Prostate Cancer Task Force and as the Leader of Advanced Prostate Cancer Care for the Alliance for Clinical Trials in Oncology, a national clinical trials group. Internationally recognized for his work focusing on the development of new treatments for advanced prostate cancer, as well as supportive care for men with prostate cancer, Dr. Ryan has published more than 200 articles and chapters in the world’s leading medical journals. He is the author of the book The Virility Paradox: The Vast Influence of Testosterone on Our Bodies, Minds, and the World We Live In released in February 2018. Dr. Ryan is the Leader of the Advanced Prostate Cancer Cadre in the Alliance for Clinical Trials in Oncology, a national clinical trials group, and past Chair of the National Cancer Institute (NCI) GU Steering Committee’s Prostate Cancer Task Force.

Should Androgen Receptor Targeting Be Given Earlier for Prostate Cancer?

ABOUT THE AUTHOR

Charles J. Ryan, MD

About The Author

Charles J. Ryan, MD

Related Posts

Prevention and Management of Rectal Toxicity

Long-Term Outcomes with Monotherapy for LR and fIR Prostate Cancer

Hypofractionation for Prostate Cancer

Comparative Outcomes: Prostate Brachytherapy vs. EBRT vs. SBRT for Low/Intermediate Risk Disease